These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 4075595)

  • 21. [Aluminum poisoning].
    Cervar M; Stavljenic A; Vukicević S
    Lijec Vjesn; 1989; 111(4-5):164-9. PubMed ID: 2671563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of iron and aluminum related osteomalacia in a long-term hemodialysis patient].
    Yamagata K; Kobayashi M; Koyama A; Narita M; Amagai H; Ohno A; Yoshikawa S
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):437-42. PubMed ID: 1875564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
    Short AI; Winney RJ; Robson JS
    Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 25. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 26. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE; Prichard S
    Int J Artif Organs; 1986 May; 9(3):167-72. PubMed ID: 3733242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of aluminium removal by desferrioxamine VIA hemodialysis in a case with aluminium bone disease.
    Terao N; Sizuki M; Ando Y; Kato K; Asano Y; Hosoda S; Suka T
    Nihon Jinzo Gakkai Shi; 1985 Sep; 27(9):1305-12. PubMed ID: 4087551
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
    Yuan B; Klein MH; Contiguglia RS; Mishell JL; Seligman PA; Miller NL; Molitoris BA; Alfrey AC; Shapiro JI
    Ren Fail; 1989; 11(2-3):91-6. PubMed ID: 2623200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Aluminum osteopathy--experience with therapy].
    Sulková S
    Vnitr Lek; 1993 May; 39(5):459-63. PubMed ID: 8351877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
    Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
    G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aluminum in chronic renal failure].
    Głuszek J; Adamczak H
    Rocz Panstw Zakl Hig; 1993; 44(1):43-8. PubMed ID: 8235341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients.
    Sprague SM; Corwin HL; Tanner CM; Wilson RS; Green BJ; Goetz CG
    Arch Intern Med; 1988 Oct; 148(10):2169-72. PubMed ID: 3178374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R
    Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of aluminium intoxication in long-term acetate Redy dialysis.
    Van de Vyver FL; Visser WJ; D'Haese PC; Silva FJ; Thomas H; De Broe ME
    Nephrol Dial Transplant; 1989; 4(6):555-62. PubMed ID: 2507978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.